Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the efficacy of its drug setrusumab in clinical studies [1][2]. Allegations - The lawsuit claims that Ultragenyx provided overly positive information about the expected results of its Phase III Orbit and Cosmic Studies for setrusumab, which was intended to treat Osteogenesis Imperfecta (OI) [2]. - Defendants allegedly concealed material adverse facts about setrusumab's potential and the risks associated with the study protocols, leading to inflated stock prices [3]. Study Results - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price dropped from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [4]. Shareholder Actions - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [5].